Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.04 | N/A | +42.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.04 | N/A | +42.86% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about the company's future. They noted significant advancements in their clinical programs and the potential for strategic collaborations.
Management highlighted progress in ongoing clinical trials.
They emphasized the importance of upcoming data releases.
The team remains focused on strategic partnerships.
The earnings report shows that Soleno Therapeutics exceeded expectations on EPS, which likely contributed to the positive stock reaction of 0.76%. However, the lack of revenue data and forward guidance leaves some uncertainty about the company's financial outlook. Investors may be encouraged by the management's focus on clinical progress and partnerships.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AXSOME THERAPEUTICS
Mar 1, 2021